Journal
MOLECULAR THERAPY-NUCLEIC ACIDS
Volume 8, Issue -, Pages 520-528Publisher
CELL PRESS
DOI: 10.1016/j.omtn.2017.08.006
Keywords
-
Categories
Funding
- National Science Council [NSC99-2320-B-001-012-MY3, MOST104-2314-B-002-228-MY3]
Ask authors/readers for more resources
The successful translation of cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade has revolutionized the concept of cancer immunotherapy. Although monoclonal antibody therapeutics remain the mainstream in clinical practice, aptamers are synthetic oligonucleotides that encompass antibody-mimicking functions. Here, we report a novel high-affinity CTLA-4-antagonizing DNA aptamer (dissociation constant, 11.84 nM), aptCTLA-4, which was identified by cell-based SELEX and high-throughput sequencing. aptCTLA-4 is relatively stable in serum, promotes lymphocyte proliferation, and inhibits tumor growth in cell and animal models. Our study demonstrates the developmental pipeline of a functional CTLA-4-targeting aptamer and suggests a translational potential for aptCTLA-4.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available